IMPAACT 2017 Adolescent/Parent Experiences With LA Cabotegravir Plus Rilpivirine for HIV Treatment
Background: The ongoing More Options for Children and Adolescents Study (MOCHA; IMPAACT 2017; Clinicaltrials.gov NCT03497676) is the first to examine use of long-acting injectable (LAI) cabotegravir (CAB) plus rilpivirine (RPV) in virologically suppressed adolescents, 12 to